knowledge -WSS

knowledge

author：focus 2025-10-02 20:46:51 - browse：85714

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Virtual care provider acquires bankrupt Pear's prescription apps

hotspot

leisure time

WSS

SEC charges former device maker CEO with $41 million fraud

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Biotech lab space demand falls sharply

FDA panel to weigh approval of NurOwn, controversial ALS drug

SEC charges former device maker CEO with $41 million fraud

Carvykti CAR

focus

knowledge

explore

Bright Health sells Medicare Advantage business to Molina

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Medicare details structure of new drug price negotiation program

HCA sued by state AG for quality issues at Mission Health

Guidelines to prevent youth baseball injuries need more muscle

Biotech stock slump in 2023: awaiting the turnaround

Medical leaders decry Supreme Court decision on affirmative action

What Congress can do to address the rural doctor shortage

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Can sheer will power keep patients alive in their dying hours?

hotspot

Second xenotransplant done with gene

It's been 20 years since Dolly the sheep. Where's my clone?

Hearing on Medicare drug price negotiation gets unusually heated

Christmas in the PICU brings some surprising joy

Senators: Long

Can sheer will power keep patients alive in their dying hours?

knowledge

hotspot

leisure time

focus